Xiaoping Zhang

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Clin Pharmacol Ther 72:10-9. 2002
  2. ncbi Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients
    Xiaoping Zhang
    Department of Clinical Pharmacology, Roche, Nutley, NJ 07110, USA
    Clin Pharmacol Ther 75:558-68. 2004
  3. ncbi Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment
    Xiaoping Zhang
    Hoffmann La Roche, Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    J Clin Pharmacol 47:510-7. 2007
  4. doi Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants
    Xiaoping Zhang
    Hoffmann La Roche, Inc, Nutley, NJ, USA
    J Clin Pharmacol 52:520-9. 2012
  5. doi Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20
    Peter N Morcos
    Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Int J Clin Pharmacol Ther 51:537-48. 2013
  6. ncbi Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide
    Indravadan H Patel
    Roche, Nutley, New Jersey 07110, USA
    Clin Pharmacokinet 44:175-86. 2005
  7. doi Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ, USA
    Int J Clin Pharmacol Ther 51:443-55. 2013
  8. pmc Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Antimicrob Agents Chemother 55:680-7. 2011
  9. doi Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis
    Xiaoping Zhang
    Hoffmann La Roche Inc, Nutley, NJ, USA
    Int J Clin Pharmacol Ther 51:620-30. 2013
  10. doi A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    J Clin Pharmacol 50:1031-8. 2010

Collaborators

Detail Information

Publications21

  1. ncbi Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Clin Pharmacol Ther 72:10-9. 2002
    ....
  2. ncbi Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients
    Xiaoping Zhang
    Department of Clinical Pharmacology, Roche, Nutley, NJ 07110, USA
    Clin Pharmacol Ther 75:558-68. 2004
    ..This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients...
  3. ncbi Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment
    Xiaoping Zhang
    Hoffmann La Roche, Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    J Clin Pharmacol 47:510-7. 2007
    ..105 h(-1), respectively. The final model was CL/F (L/h) = 1.31 . (body weight/33 [kg])(0.721). Age did not affect enfuvirtide exposure. These results confirm the appropriateness of body weight-based pediatric enfuvirtide dosing...
  4. doi Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants
    Xiaoping Zhang
    Hoffmann La Roche, Inc, Nutley, NJ, USA
    J Clin Pharmacol 52:520-9. 2012
    ..PubMed search and Roche postmarketing data did not reveal publications or reports directly presenting the effect of saquinavir on QT/QTc or causing torsade de pointes...
  5. doi Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20
    Peter N Morcos
    Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Int J Clin Pharmacol Ther 51:537-48. 2013
    ..To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tocilizumab with and without rHuPH20 (a recombinant human hyaluronidase) in healthy volunteers...
  6. ncbi Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide
    Indravadan H Patel
    Roche, Nutley, New Jersey 07110, USA
    Clin Pharmacokinet 44:175-86. 2005
    ..In HIV-1-infected paediatric patients, subcutaneous dosages based on bodyweight (2 mg/kg twice daily) produce pharmacokinetics broadly similar to those observed in adults administered 90 mg twice daily...
  7. doi Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ, USA
    Int J Clin Pharmacol Ther 51:443-55. 2013
    ..The objective of the study was to determine pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab including absolute PK and PD bioavailabilities following subcutaneous (s.c.) administration...
  8. pmc Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Antimicrob Agents Chemother 55:680-7. 2011
    ..The AUC(0-96) of rifabutin was not affected, and C(max) increased by 68%. Monitoring of neutropenia and liver enzyme levels is recommended for patients receiving rifabutin with saquinavir-ritonavir BID...
  9. doi Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis
    Xiaoping Zhang
    Hoffmann La Roche Inc, Nutley, NJ, USA
    Int J Clin Pharmacol Ther 51:620-30. 2013
    ..To investigate the pharmacokinetics, pharmacodynamics, safety and efficacy of subcutaneous tocilizumab 162 mg weekly (QW) or every other week (Q2W) in rheumatoid arthritis patients on methotrexate...
  10. doi A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    J Clin Pharmacol 50:1031-8. 2010
    ..The results of this study suggest that dose adjustments for either drug are not necessary when concomitantly administered and that pamapimod can decrease pharmacodynamic markers of disease activity...
  11. doi Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis
    Xiaoping Zhang
    Hoffmann La Roche Inc, Nutley, NJ, USA
    Expert Rev Clin Pharmacol 6:123-37. 2013
    ..Proportions of patients achieving clinical end points were comparable across exposure quartiles, suggesting that pharmacokinetic exposures are within the plateau of the exposure-response curve...
  12. doi Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
    Expert Rev Clin Pharmacol 4:539-58. 2011
    ..Tocilizumab exposures are not affected by common concomitant medications in RA patients, but decreased IL-6 activity resulted in increased CYP3A4 activity and hence decreased exposures of CYP3A4 substrates...
  13. doi Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffman La Roche Inc, Nutley, NJ 07110, USA
    J Clin Pharmacol 49:534-9. 2009
    ..60 ms for day -1 time-matched baseline ECGs, and 1.65 ms for no baseline correction. Predose baseline methods (3 or 1 triplicate ECGs) are superior to the day -1 time-matched baseline correction or without baseline correction...
  14. doi Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement
    Hong C Shen
    Merck Research Laboratories, Merck and Co, Inc, Rahway, NJ 07065 0900, USA
    J Med Chem 52:5009-12. 2009
    ..With minimal off-target activity and a good PK profile, the benchmark 2d exhibited remarkable in vitro and ex vivo target engagement. The eutomer entA-2d also elicited vasodilation effect in rat mesenteric artery...
  15. ncbi Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients
    Kiat Ruxrungtham
    Thai Red Cross AIDS Research Centre, Rama 4 Road, Bangkok 10330, Thailand
    J Clin Pharmacol 44:793-803. 2004
    ..Thus, no dosage adjustments are warranted when enfuvirtide is coadministered with low-dose ritonavir or saquinavir boosted with a low dose of ritonavir...
  16. ncbi Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients
    Jacob P Lalezari
    Quest Clinical Research, 2300 Sutter Street, Suite 202, San Francisco, CA 94115, USA
    J Clin Virol 28:217-22. 2003
    ..Enfuvirtide is the first in a new class of antiretrovirals (ARVs), the fusion inhibitors, and the first ARV to be administered by subcutaneous (s.c.) injection...
  17. ncbi Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients
    Diane R Mould
    Projections Research Inc, Phoenixville, PA, USA
    Clin Pharmacol Ther 77:515-28. 2005
    ....
  18. ncbi Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide
    Mark Alastair Boyd
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Pathumwan, Bankok, Thailand
    J Clin Pharmacol 43:1382-91. 2003
    ..There were no unexpected effects of rifampicin on the short-term antiviral effect or safety of the administered antiretroviral treatment. The pharmacokinetics of enfuvirtide are not induced by a 10-day pretreatment with rifampicin...
  19. pmc Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages
    Li Wan
    Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey 08854, USA
    Bioconjug Chem 19:28-38. 2008
    ..The convenience, flexibility and possible limitations of this nanocarrier approach are discussed...
  20. ncbi Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells
    Xiaoping Zhang
    Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:7181-90. 2007
    ..In this study, we investigated whether synthetic induction of c-Fos/AP-1 by 12-O-tetradecanoylphorbol-13-acetate (TPA) converts the phenotype of TRAIL-resistant prostate cancer cells to a TRAIL-sensitive phenotype in vitro and in vivo...
  21. ncbi Lysine 144, a ubiquitin attachment site in HIV-1 Nef, is required for Nef-mediated CD4 down-regulation
    Yong Jiu Jin
    Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 180:7878-86. 2008
    ..These data suggest that ubiquitination of Nef, particularly diubiquitination of the lysine 144, is necessary for Nef-mediated CD4 down-regulation...